Gary Bellinger

Gary Bellinger is a Researcher at the Yale University School of Medicine, affiliated with the Politi Lab. He holds roles including Lab Manager and Research Associate II-MS, specializing in rodent surgery and therapeutic interventions. His primary research focuses on cancer metabolism, autoimmune diseases, and surgical techniques in small animal models. Notable contributions include studies on pyruvate kinase isoforms in tumor progression and the role of metabolic pathways in cancer cell survival.

Education:

• Specialist in Rodent Surgery, Weill Cornell Medical Center (2013)
• Senior Research Associate II, Harvard Medical School (2012)
• Senior Associate Scientist, Pfizer Global Research & Development (2008)
• Research Associate, Yale School of Medicine (2007)
• Bachelor of Science in Biology, Southern CT State University (1999)

Research Interests:

Dr. Bellinger’s work centers on understanding metabolic reprogramming in cancer cells, particularly how pyruvate kinase isoforms influence tumor growth and drug resistance. He also investigates therapeutic strategies targeting epigenetic modifications (e.g., demethylation therapies) in head and neck cancers. His surgical expertise supports preclinical models for evaluating drug efficacy and tolerance in small animals.

Publications:

His research spans over two decades, with key contributions in Cancer Research, Cell, and Molecular Cell. Recent work highlights the suppressive role of pyruvate kinase M1 in prostate cancer and the metabolic dependency of cancer cells on glutamine under metformin treatment.

Labs & Teams:

As part of the Politi Lab, he collaborates on translational studies linking metabolic pathways to cancer therapy. His team’s work bridges basic science and clinical applications, emphasizing drug development and surgical interventions in oncology.